Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119

BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER

Gottesman, M. M., & PASTAN, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,569

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

Campo, E., Swerdlow, S. H., Harris, N. L., Pileri, S. A., Stein, H., & Jaffe, E. S. (2011) · Blood · doi:10.1182/blood-2011-01-293050 · Cited by 2,007

Myelodysplastic Syndromes

Greenberg, P. L., Attar, E. C., Bennett, J. M., Bloomfield, C. D., Borate, U., Castro, C. M. D., Deeg, H. J., Frankfurt, O., Gaensler, K. M. L., Garcia-Manero, G., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0104 · Cited by 1,625

Age and acute myeloid leukemia

Appelbaum, F. R., Gundacker, H. M., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,371

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Bloomfield, C. D., Lawrence, D. D., Byrd, J. C., Carroll, A. J., Pettenati, M. J., Tantravahi, R. V., Patil, S., Davey, F. R., Berg, D. T., Schiffer, C. A., et al. (1998) · PubMed · Cited by 682

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

Kantarjian, H. M., O'Brien, S. M., Cortes, J. E., Giles, F. J., Faderl, S. H., Jabbour, E. J., Garcia‐Manero, G., Wierda, W. G., Pierce, S. A., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 608

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Kayser, S., Döhner, K., Krauter, J., Köhne, C.-H., Horst, H. A., Held, G., von Lilienfeld-Toal, M., Wilhelm, S., Kündgen, A., Götze, K., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301713 · Cited by 487

Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromesPreprint

Chen, Y.-H., Bi, T., Xu, M. Q., Lee, J., Lu, W. S., Zhuang, M., Velarde, A. M., McCurry, D., Yang, H., Alatrash, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.17.682671 · Cited by 1

Ex vivo-model design and evaluation of the sensitivity of blast cells to chemotherapy as a way to personalize the treatment of acute myeloid leukemia

Polyakov, A. S., Noskov, Y. A., Nikitin, Y. V., Tyrenko, V. V., Kolubaeva, S. N., Bogdanov, A. N., Semelev, V. N., Петрова, О. Р., Bondarchuk, S. V., Zhogolev, D., et al. (2019) · Oncohematology · doi:10.17650/1818-8346-2019-14-2-59-69

Characterization of secondary and therapy-related acute myeloid leukemia

Nilsson, C. C. (2020) · Figshare

Insights into the Pathobiology of Secondary AML

Jain, T., & Rampal, R. K. (2020) · Hematologic malignancies · doi:10.1007/978-3-030-53633-6_3

Novel Strategies in the Treatment of Older Patients with Acute Myeloid Leukemia

Kadia, T. M. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(21)01207-6

Acute Myeloid Leukemias After the Treatment of Classical Hodgkin’s Lymphoma: A Literature Review

Danilenko, A. A., Шахтарина, С. В., & Falaleeva, N. A. (2022) · Clinical oncohematology · doi:10.21320/2500-2139-2022-15-4-414-423

A second look at the status quo for secondary acute myeloid leukemia after hypomethylating agents

Peters, D. T., & Zeidner, J. F. (2025) · Cancer · doi:10.1002/cncr.35838

Additional file 1 of A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Short, N. J., Müftüoğlu, M., Ong, F., Nasr, L. F., Macaron, W., Bravo, G. M., Alvarado, Y., Basyal, M., Daver, N., Dinardo, C. D., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23650176

Additional file 1 of Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Short, N. J., Venugopal, S., Qiao, W., Kadia, T. M., Ravandi, F., Macaron, W., Dinardo, C. D., Daver, N., Konopleva, M., Borthakur, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19092711

Cladribine, low-dose cytarabine, and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: A global perspective

Dalle, I. A., Yassine, A., Awada, A., Chakhachiro, Z. I., Mahfouz, R. A., Moukalled, N. M., Cheikh, J. E., & Bazarbachi, A. A. (2026) · Current Research in Translational Medicine · doi:10.1016/j.retram.2026.103576

Etude du rôle du corégulateur transcriptionnel RIP140 dans le métabolisme glucidique et la différenciation des cellules cancéreuses

Jacquier, V. (2020) · theses.fr (ABES) · doi:10.70675/91518059z9711z4776z906dza15372a70c36

Ciblage thérapeutique de la protéine CDK6 dans les leucémies aiguës myéloïdes

Brault, L. M. (2022) · theses.fr (ABES) · doi:10.70675/26bca708z5a9az4d80z85bfz9159b330b1e8

Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes

Matsukawa, T., Yoshida, S. Y., Onozawa, M., Fujii, F., Nagai, J., Takahashi, T., Ota, S., Hashiguchi, J., Mori, A., Miyagishima, T., et al. (2026) · Figshare · doi:10.6084/m9.figshare.31310112

Differential Induction Among Younger Patients Diagnosed with Secondary Acute Myelogenous Leukemia Is Feasible By Cytogenetic/Molecular Risk Stratification

Afrough, A., Talukder, R., Yellapragada, S. V., Teegavarapu, P. S., Mims, M. P., & Rivero, G. (2019) · Blood · doi:10.1182/blood-2019-129183

Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML

Lalayanni, C., Gavriilaki, E., Athanasiadou, A., Iskas, M., Papathanasiou, M., Marvaki, A., Dimou-Mpesikli, S., Papaioannou, G., Mallouri, D., Batsis, I., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.09.019 · Cited by 17

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation

Senapati, J., Kantarjian, H. M., Haddad, F., Short, N. J., Borthakur, G. M., Kanagal‐Shamanna, R., Tang, G., Jabbour, E. J., Dinardo, C. D., Daver, N. G., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27561 · Cited by 17

Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk

Kim, S., Yoon, S., Hong, J., Shin, D., Koh, Y., Byun, J. M., & Kim, I. (2020) · Anticancer Research · doi:10.21873/anticanres.14269 · Cited by 17